Exscientia PLC ADR EXAI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EXAI is a good fit for your portfolio.
News
-
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 25, 2024 in Exscientia plc Lawsuit - EXAI
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Exscientia, and Akero and Encourages Investors to Contact the Firm
-
ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Exscientia plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – EXAI
-
Investors in Exscientia plc Should Contact The Gross Law Firm Before June 25, 2024 to Discuss Your Rights - EXAI
-
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Exscientia p.l.c. (EXAI) Investors
-
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Exscientia
-
Exscientia plc Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights – EXAI
-
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Exscientia p.l.c. (EXAI) on Behalf of Investors
Trading Information
- Previous Close Price
- $5.09
- Day Range
- $4.67–5.24
- 52-Week Range
- $3.86–9.12
- Bid/Ask
- $4.60 / $4.80
- Market Cap
- $590.17 Mil
- Volume/Avg
- 2,216 / 749,343
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 23.24
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Exscientia PLC is engaged in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of novel therapeutic compounds. The company’s technology platform combines human and computational capabilities to accelerate the process of designing novel, safe, and efficacious compounds for clinical testing in humans. The company is focused on the discovery and development of small-molecule drug candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 483
- Website
- https://www.exscientia.ai
Valuation
Metric
|
EXAI
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.49 |
Price/Sales | 23.24 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
EXAI
|
---|---|
Quick Ratio | 6.10 |
Current Ratio | 6.22 |
Interest Coverage | −166.49 |
Quick Ratio
EXAI
Profitability
Metric
|
EXAI
|
---|---|
Return on Assets (Normalized) | −21.10% |
Return on Equity (Normalized) | −32.33% |
Return on Invested Capital (Normalized) | −31.04% |
Return on Assets
EXAI
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zwffywzsl | Ljwf | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qvbvvqtvk | Ppxkyt | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dslfpgbd | Yvzjx | $103.7 Bil | |
MRNA
| Moderna Inc | Cymvymlxy | Zvpl | $47.9 Bil | |
ARGX
| argenx SE ADR | Lylyjcmpp | Tqncc | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Phhlvpyf | Wdcv | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qctjgqmqs | Tqqjx | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Sjbppqhw | Zsdvxv | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cfgdgmvwtz | Hhstk | $12.8 Bil | |
INCY
| Incyte Corp | Gsfrhwbb | Khmzzc | $12.1 Bil |